Mobile

Open-label, multi-center, two-stage, age stratified, pharmacokinetic, safety, and efficacy study in children 2 month to < 2 years of age undergoing Magnevist Injection enhanced MRI

Update Il y a 5 ans
Reference: EUCTR2009-013081-17

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Stage 1: To determine the optimal efficacious dose (0.05 mmol/kg or 0.1 mmol/kg BW) of Magnevist Injection Stage 2: To evaluate pharmacokinetics of Magnevist Injection at the optimal efficacious dose from stage 1

Inclusion criteria

  • Contrast-enhanced MRI in children 2 month to < 2 years

Links